Insider trade

Officer sold ~$284K of ALKS shares in the open market

Traded Oct 15, 2025 · Filed Oct 15, 2025

Why it stands out

Alkermes's R&D, Chief Medical Officer sold $284K of Alkermes shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$283,776

Shares × reported transaction price

Timing vs results

78 days after results of Jul 29, 2025, 7 days before results of Oct 22, 2025

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−2.5%	+1.7%	−4.2%
30 days	−4.8%	+0.8%	−5.5%
90 days	−0.6%	+4.5%	−5.1%
180 days	+10.0%	+5.1%	+4.8%

Past results only. Not a forecast.

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.51 to $31.60. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

11mo ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance11mo ago

11mo ago

Derivative exercise or conversion — not an open-market buy.